NCT03941743View on ClinicalTrials.gov

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

June 5, 2020

Study Completion Date

November 23, 2021

Conditions
Breast Carcinoma
Interventions
DRUG

Fingolimod

Given PO

DRUG

Fingolimod Hydrochloride

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

23298

Virginia Commonwealth University/ Massey Cancer Center, Richmond

43212

The Ohio State University, Columbus

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT03941743 - Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter